GLP-1 constipation: why it happens and what to discuss with a clinician

Most people starting a GLP-1 medication brace for nausea. Constipation gets less airtime, but it is one of the most common digestive complaints, and it tends to arrive quietly — a few days between bowel movements, harder stools, a sense of fullness that lingers. Knowing why it happens makes it less alarming and easier to talk through with a clinician.

What strong evidence says

Constipation is a well-documented, common side effect of GLP-1 receptor agonists and the dual GIP/GLP-1 agonists in the same family. It is not a rare or surprising reaction — it is printed on the approved drug labels. The U.S. prescribing information for semaglutide lists constipation among the most frequent adverse reactions, reported by roughly one in four people treated versus about one in ten on placebo. The large randomized trials that established these medicines — including the STEP program for semaglutide and SURMOUNT-1 for tirzepatide — consistently found gastrointestinal effects to be the most common adverse events, mostly mild to moderate.

The mechanism is closely tied to how these drugs work. GLP-1 receptor agonists are well documented to slow gastric emptying — the rate at which the stomach passes food into the intestine — and are thought to slow movement through the lower gut as well, though the evidence for that broader effect is less firm. That delay in the stomach is part of how they blunt appetite and flatten post-meal blood sugar. When transit slows, food and waste can spend longer in the colon, where more water is reabsorbed, leaving stool drier, harder, and less frequent. On top of that, a smaller appetite usually means eating less food and drinking less fluid and fiber, which can compound the slowdown. So constipation is a largely predictable consequence of how the medicine acts, not a sign something has gone wrong.

For most people it is most noticeable during the early weeks and the dose-adjustment phase, and it often eases as the body adjusts. This is established for the approved medicines used as approved. (Retatrutide, the triple-receptor agonist studied in the 2023 phase 2 trial cited here, showed the same gastrointestinal pattern but remains investigational and is not FDA-approved.)

What weaker evidence suggests

The everyday tactics people reach for — more fluid, more dietary fiber, staying physically active, regular meal timing — rest on weaker, more general evidence. Fiber and fluid supporting gut motility is reasonable and broadly accepted, but the support for it specifically in people on GLP-1 therapy is limited rather than proven by dedicated trials; much of it is sensible extrapolation from how constipation is managed in general. There is a genuine tension worth naming: appetite is lower precisely when fiber and fluid would help most, so getting enough can take deliberate effort.

How strongly any one person is affected also varies, and the evidence does not let anyone predict in advance who will struggle and who will sail through. Some people barely notice it; others find it one of the more bothersome parts of the early months. Over-the-counter approaches exist, but which one fits depends on individual circumstances and other medications — that is a conversation for a clinician or pharmacist, not a one-size answer.

What is unknown

Several things remain genuinely uncertain. There is no reliable way to predict who will get significant constipation before starting. The long-term effects of sustained, slowed gut motility are not well characterized. The best specific management strategy for GLP-1-related constipation has not been settled by head-to-head trials in this population, so most advice is borrowed from general practice. And while severe complications are rare, the boundary between ordinary, expected constipation and an early warning of something more serious — like a bowel that has stopped moving — is exactly why the red flags below matter.

Questions to ask a clinician

• Given how little I may feel like eating, how do I realistically get enough fluid and fiber?
• Are any of my other medications likely to make constipation worse?
• What over-the-counter options, if any, are appropriate for me — and which should I avoid?
• At what point does constipation move from “manage at home” to “call you”?
• Could constipation affect how my other oral medications are absorbed, since this drug slows the stomach?
• If it becomes hard to tolerate, what are the options — adjusting the plan, or pausing?

Red flags / when to seek care

Most constipation on these medicines is uncomfortable but ordinary. Some patterns are not, and they warrant prompt medical attention rather than waiting it out:

• No bowel movement for several days together with worsening abdominal pain, bloating, or a visibly swollen belly — especially if you also cannot pass gas.
• Persistent vomiting, particularly alongside the above, which can signal that the gut is not moving (the drug labels carry warnings about this kind of severe gastrointestinal event).
• Severe or sharp abdominal pain that is new or escalating.
• Blood in the stool, fever, or feeling acutely unwell along with the constipation.

These can be signs of a bowel obstruction or related emergency. If any of them appear, contact a clinician without delay — and if it feels like an emergency, call your local emergency number. A symptom in your body is not a claim to weigh; it is a reason to get help.

This page summarizes published evidence for education only. It is not medical advice, and it does not replace a conversation with a clinician who knows your history.